Open
Does insulin cause more adverse events & safety versus placebo?
Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.09 (range 0.00–0.55)
- Trials for
- 1
- Trials against
- 8
- Inconclusive
- 0
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 138
- With posted results
- 65
- Published papers
- 12
Of 42 decided analyses: 8 favor insulin, 13 find no difference, 21 favor the comparator.
Papers
- Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.Trial report · 2021
- Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.Meta-analysis / systematic review · 2024
- Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.Meta-analysis / systematic review · 2026
- Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.Meta-analysis / systematic review · 2017
- [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].Meta-analysis / systematic review · 2016
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.Meta-analysis / systematic review · 2016
Trials
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes MellitusNCT02607306 · 10 posted results
- A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week ExtensionNCT01336023 · 2 posted results
- A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 DiabetesNCT01392573 · 1 posted result
- The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin TherapyNCT01618162 · 2 posted results
- The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)NCT01676116 · 2 posted results
- A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and SulfonylureaNCT00960661 · 1 posted result
- An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 DiabetesNCT01123980 · 1 posted result
- Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)NCT03268005 · 15 posted results